18 Jul BlueWhale Bio
Peter Keller, CEO
Oct. 8 | 10:15am | FLW Ballroom G
Philadelphia, PA
(Private)
At BlueWhale Bio, we’re focused on transforming T cell manufacturing with our Synecta™ T1 Cell-Derived Nanoparticles. Our platform is designed to improve T cell activation, proliferation, and overall quality—critical elements for successful CAR-T and other cell therapies. Unlike traditional methods that rely on beads or feeder cells, our nanoparticles offer a tunable, cell-free solution that mimics natural stimulation while simplifying and streamlining the manufacturing process. This means better consistency, higher yields, and reduced costs for our partners. We work closely with both academic labs and commercial biotech teams to support everything from early discovery through scale-up. Headquartered in the U.S., we collaborate with leaders across the immunotherapy space to help accelerate the next generation of cell therapies. Our goal is to remove the bottlenecks in T cell expansion and enable more reliable, scalable, and effective manufacturing—making life-changing therapies more accessible to patients.
